Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM-819 in healthy older adults and Parkinson's disease
NCT05670782Phase 2Active, not recruiting
- Sponsor
- FAScinate Therapeutics
- Start
- Jul 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KM-819 in Parkinson's disease (PD), sponsored by FAScinate Therapeutics. Started Jul 2022; status: active, not recruiting.
02
Drugs
KM-819
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05670782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05670782.